The Liquidity Challenge of Real-World Medical Assets

Beyond data, another critical bottleneck lies in the illiquidity of Real-World Medical Assets (RWA). These assets include, but are not limited to:

• Intellectual Property: Such as drug patents, biotechnology patents, medical method patents, etc.

• Commercialization Right: Such as medical equipment manufacturing rights, distribution licenses, operation rights, etc.

• R&D Data and Outcome: Such as clinical trial datasets, research project outputs, innovation validation data, etc.

• Comprehensive Innovation Assets: Such as integrated healthcare solution packages combining intellectual property and data.

Such assets are the backbone of biomedical progress, yet remain largely untapped due to complex valuation, lengthy transaction cycles, and limited trust mechanisms. Early-stage biotech projects and research outputs, often unstandardized and illiquid, struggle to attract sustainable funding — constraining innovation efficiency across the healthcare sector.